Biomarker Consortium launches
This article was originally published in The Gray Sheet
Executive SummaryThe American College of Radiology Imaging Network's (ACRIN) planned clinical trial exploring the use of fluorodeoxyglucose positron emission tomography (FDG-PET) to evaluate non-Hodgkins lymphoma and lung cancer patients' response to therapy is the first project supported by the Biomarker Consortium, a newly formed research partnership between the Foundation for the National Institutes of Health, NIH, FDA, CMS and industry and patient groups, according to an Oct. 5 release. The consortium will identify and validate new biological markers to advance the science of personalized medicine. "Imaging tests such as PET scanning can potentially reduce both suffering and cost for cancer patients by providing better selection of appropriate treatment and determining earlier ... whether treatment will be effective," ACRIN explains. Depression and diabetes are further areas of prospective study cited by the consortium...
You may also be interested in...
US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.
Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.
The company has reached a broad opioid settlement agreement in principle under which its specialty generics subsidiaries would file for Chapter 11 bankruptcy and Mallinckrodt's branded business would operate separately.